A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01

Clinical and Translational Oncology

Volumn 12, Issue 7, 2010, Pages 503-508

  Bellmunt, Joaquim ^a   Maroto Rey, Pablo ^b   Trigo, José M ^c   Carles, Joan ^a   Guillem, Vicente ^d   López Martín, José A ^e   Antón Torres, Antonio ^f   Urruticoechea, Leyrer ^g  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g Bayer Schering Pharma   (Spain)

Author keywords

Angiogenesis inhibitors; Cytokines; Renal cell carcinoma; Sorafenib

Indexed keywords

SORAFENIB;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BILIRUBIN BLOOD LEVEL; BONE METASTASIS; BONE PAIN; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISORIENTATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DYSPNEA; ERYTHEMA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KIDNEY CARCINOMA; LIMB PAIN; LUNG METASTASIS; MALE; MUSCLE WEAKNESS; NAUSEA; OLIGURIA; OVERALL SURVIVAL; PATIENT ATTITUDE; PERIPHERAL EDEMA; PHOSPHATE BLOOD LEVEL; PROGRESSION FREE SURVIVAL; PROTHROMBIN TIME; RECTUM HEMORRHAGE; RESPONSE TIME; SIDE EFFECT; STOMATITIS; SYNCOPE; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER ABDOMINAL PAIN; URIC ACID BLOOD LEVEL; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BONE NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; REMISSION INDUCTION;

EID: 77956019404     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0544-2     Document Type: Article

References (25)

1. J. Ferlay P. Autier M. Boniol, et al. 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 581 592 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D 17287242
2. S.A. Karumanchi J. Merchan V.P. Sukhatme 2002 Renal cancer: molecular mechanisms and newer therapeutic options Curr Opin Nephrol Hypertens 11 37 42 10.1097/00041552-200201000-00006 11753085
3. B. Ljungberg D.C. Hanbury M.A. Kuczyk, et al. 2007 Guidelines on renal cell carcinoma Eur Urol 51 1502 1510 10.1016/j.eururo.2007.03.035 17408850
4. A. Lopez-Beltran M. Scarpelli R. Montironi Z. Kirkali 2006 2004 WHO classification of the renal tumors of the adults Eur Urol 49 798 805 10.1016/j.eururo.2005.11.035 16442207
5. J. Bellmunt S. Negrier B. Escudier, et al. 2009 The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce Crit Rev Oncol Hematol 69 64 72 10.1016/j.critrevonc.2008.08.002 18774306
6. Coppin C, Porzsolt F, Kumpf J et al (2000) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev CD001425
7. B. Escudier T. Eisen W.M. Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D 17215530
8. B. Escudier A. Pluzanska P. Koralewski, et al. 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103 2111 10.1016/S0140-6736(07)61904-7 18156031
9. G. Hudes M. Carducci P. Tomczak, et al. 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D 17538086
10. R.J. Motzer T.E. Hutson P. Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529
11. R.J. Motzer B. Escudier S. Oudard, et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D 18653228
12. B.I. Rini S. Halabi J.E. Rosenberg, et al. 2008 Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 5422 5428 10.1200/JCO.2008.16.9847 1:CAS:528:DC%2BD1MXhslClsA%3D%3D 18936475
13. Bukowski RM, Eisen T, Szczylik C et al (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25: abstract 5023
14. Escudier B, Szczylik C, Eisen T et al (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol 23:abstract 4510
15. Escudier B, Szczylik C, Demkow T et al (2006) Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naive patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24:abstract 4501
16. R.J. Motzer J. Bacik L.H. Schwartz, et al. 2004 Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma J Clin Oncol 22 454 463 10.1200/JCO.2004.06.132 14752067
17. P. Therasse S.G. Arbuck E.A. Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
18. S. Negrier B. Escudier F. Gomez, et al. 2002 Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie Ann Oncol 13 1460 1468 10.1093/annonc/mdf257 1:STN:280:DC%2BD38vjvVGitA%3D%3D 12196373
19. B. Escudier C. Szczylik T.E. Hutson, et al. 2009 Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 1280 1289 10.1200/JCO.2008.19.3342 1:CAS:528:DC%2BD1MXktFKhsb8%3D 19171708
20. Szczylik C, Cella D, Eisen T et al (2008) Comparison of kidney cancer symptoms and quality of life in renal cell cancer patients receiving sorafenib vs interferon-alpha. J Clin Oncol 26: abstract 9603
21. M.J. Ratain T. Eisen W.M. Stadler, et al. 2006 Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505 2512 10.1200/JCO.2005.03.6723 1:CAS:528:DC%2BD28XmtVOmtrk%3D 16636341
22. Beck J, Bajetta E, Escudier B et al (2007) A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur J Cancer [Suppl 7]:244 abstract 4506
23. Knox JJ, Figlin RA, Stadler WM et al (2008) The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy. J Clin Oncol 25:abstract 5011
24. Nexavar® (sorafenib) Summary of product characteristics. Bayer Schering Pharma AG, Berlin, Germany. November 2009
25. Bellmunt J, Mulders P, Szczylik C, Porta C (2008) Defining a new patient-focused approach to renal cell carcinoma. Ann Oncol 19(viii 197):abstract 612P